Research that Identifies
Undiscovered Value in the MicroCap Market



SIMULATIONS PLUS, INC.

Simulations Plus Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Updated Research Report (Dated 04/24/2017)

Symbol: SLP
Analyst: Howard Halpern
Taglich Rating: Buy
Price Target: $13.35
Time Horizon: 12 Months
Rating Established: July 17, 2015
Price When Established: $6.68
Most Recent Report: April 24, 2017
Price When Issued: $11.55


What's New

Simulations Plus Reports Preliminary 3Q17 Sales

On June 15, 2017, Simulations Plus reported preliminary revenues for its third quarter of fiscal 2017, ended May 31, 2017.

SLP expects to report revenues increased 11.3% to $6.7 million. Sales increased at the company’s Buffalo subsidiary (Cognigen) by 29.4% or nearly $400,000 to $1.7 million.

Our current forecast calls for fiscal third quarter 2017 revenues of $6.5 million.


Simulations Plus to Acquire DILIsym Services

On May 1, 2017, Simulations Plus announced it entered into an agreement to acquire DILIsym Services. Upon final due diligence and other closing conditions the acquisition should occur on or about June 1, 2017. DILIsym Services will be merged into a wholly owned subsidiary of Simulations Plus. Simulations Plus staff will increase to 79 from 68. The deal should be immediately accretive adding at least $3 in revenue in FY18.

Established in 2015, DILIsym Services is a profitable company that provides drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry. The company’s other products include MITOsym® for simulating in vitro mitochondrial function, SimPops™ for evaluating the impact of patient variability, and a new product in development called NAFLDsym™ for the study of nonalcoholic fatty liver disease – a worldwide disease with few available treatment options. In FY16 the company had net income of $720,000 on revenue of approximately $3 million.

The agreement calls for Simulations Plus to pay the shareholders of DILIsym Services $10 million, comprised of $5 million in cash and an a $5 million earn-out over three-years. An eighteen-month $1 million hold back will be used to satisfy any indemnifiable claims that may arise pursuant to the terms of the agreement.


Company Description

Simulations Plus, Inc., based in Lancaster, California, is a developer of drug discovery and development software, which is licensed to and used in drug research by major pharmaceutical and biotechnology companies worldwide.


Company Reports

Updated Research Report (Dated April 24, 2017)
Updated Research Report (Dated January 13, 2017)
Updated Research Report (Dated December 2, 2016)
Updated Research Report (Dated August 3, 2016)
Updated Research Report (Dated April 22, 2016)
Updated Research Report (Dated January 27, 2016)
Updated Research Report (Dated December 9, 2015)
Updated Research Report (Dated July 17, 2015)
Updated Research Report (Dated April 23, 2015)
Updated Research Report (Dated January 29, 2015)
Updated Research Report (Dated December 16, 2014)
Research Note Released (Dated September 8, 2014)
Updated Research Report (Dated July 23, 2014)
Updated Research Report (Dated April 28, 2014)
Updated Research Report (Dated January 17, 2014)
Updated Research Report (Dated November 26, 2013)
Updated Research Report (Dated July 18, 2013)
Updated Research Report (Dated April 18, 2013)
Updated Research Report (Dated January 18, 2013)
Updated Research Report (Dated December 10, 2012)
Updated Research Report (Dated July 16, 2012)
Updated Research Report (Dated April 18, 2012)
Updated Research Report (Dated January 23, 2012)
Updated Research Report (Dated December 15, 2011)
Updated Research Report (Dated July 22, 2011)
Updated Research Report (Dated May 10, 2011)
Updated Research Report (Dated January 21, 2011)
Updated Research Report (Dated December 22, 2010)
Updated Research Report (Dated July 27, 2010)
Updated Research Report (Dated April 27, 2010)
Updated Research Report (Dated February 4, 2010)
Updated Research Report (Dated December 18, 2009)
Updated Research Report (Dated July 28, 2009)
Updated Research Note (Dated June 15, 2009)
Updated Research Update (Dated April 30, 2009)
Updated Earnings Note (Dated April 15, 2009)
Updated Research Report (Dated February 4, 2009)
Updated Earnings Note (Dated January 15, 2009)
Updated Research Report (Dated December 15, 2008)
Updated Research Report (Dated December 15, 2008)
Updated Research Report (Dated August 18, 2008)
Updated Earnings Note (Dated July 15, 2008)
Updated Research Report (Dated May 12, 2008)
Updated Earnings Note (Dated April 15, 2008)
Updated Research Report (Dated February 1, 2008)
Updated Earnings Note (Dated January 14, 2008)
Updated Research Report (Dated December 14, 2007)
Updated Earnings Note (Dated November 26, 2007)
Updated Research Report (Dated July 16, 2007)
Updated Research Report (Dated April 26, 2007)
Updated Research Note (Dated March 26, 2007)
Updated Research Report (Dated January 31, 2007)
Updated Research Report (Dated December 26, 2006)
Updated Research Report (Dated August 7, 2006)
Updated Research Report (Dated May 8, 2006)
Updated Research Report (Dated February 16, 2006)
Updated Research Report (Dated December 22, 2005)
Updated Research Report (Dated July 26, 2005)
Updated Research Report (Dated May 10, 2005)
Updated Research Report (Dated February 17, 2005)
Updated Research Report (Dated December 20, 2004)
Initial Research Report (Dated July 26, 2004)

Disclaimer

The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. The company paid for the first year of distribution a fee of $21,000 (USD) on May 2004, and since August 2005 pays a monthly monetary fee of $1,750 (USD) to Taglich Brothers, Inc. for the creation and dissemination of research reports. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.